ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, Andrew J.; Leverson, Joel D.; Boghaert, Erwin R.; Ackler, Scott L.; Catron, Nathaniel D.; Chen, Jun; Dayton, Brian D.; Ding, Hong; Enschede, Sari H.; Fairbrother, Wayne J.; Huang, David C.S.; Hymowitz, Sarah G.; Jin, Sha; Khaw, Seong Lin; Kovar, Peter J.; Lam, Lloyd T.; Lee, Jackie; Maecker, Heather L.; Marsh, Kennan C.; Mason, Kylie D.; Mitten, Michael J.; Nimmer, Paul M.; Oleksijew, Anatol; Park, Chang H.; Park, Cheol-Min; Phillips, Darren C.; Roberts, Andrew W.; Sampath, Deepak; Seymour, John F.; Smith, Morey L.; Sullivan, Gerard M.; Tahir, Stephen K.; Tse, Chris; Wendt, Michael D.; Xiao, Yu; Xue, John C.; Zhang, Haichao; Humerickhouse, Rod A.; Rosenberg, Saul H.; Elmore, Steven W.

doi:10.1038/nm.3048

Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Journal Article · Fri Apr 15 00:00:00 EDT 2016 · Nature Medicine

DOI:https://doi.org/10.1038/nm.3048· OSTI ID:1247361

Souers, Andrew J.; Leverson, Joel D.; Boghaert, Erwin R.; Ackler, Scott L.; Catron, Nathaniel D.; Chen, Jun; Dayton, Brian D.; Ding, Hong; Enschede, Sari H.; Fairbrother, Wayne J.; Huang, David C.S.; Hymowitz, Sarah G.; Jin, Sha; Khaw, Seong Lin; Kovar, Peter J.; Lam, Lloyd T.; Lee, Jackie; Maecker, Heather L.; Marsh, Kennan C.; Mason, Kylie D. more »

AbbVie

Cite

Export

Save

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: INDUSTRY

OSTI ID:: 1247361

Journal Information:: Nature Medicine, Vol. 19, Issue 01, 2013; ISSN 1078-8956

Publisher:: Nature Publishing Group

Country of Publication:: United States

Language:: ENGLISH

References (43)

Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells Campàs, Clara; Cosialls, Ana M.; Barragán, Montserrat Experimental Hematology, Vol. 34, Issue 12 https://doi.org/10.1016/j.exphem.2006.07.008	journal	December 2006
MiR-15a and miR-16-1 cluster functions in human leukemia Calin, George A.; Cimmino, Amelia; Fabbri, Muller Proceedings of the National Academy of Sciences, Vol. 105, Issue 13 https://doi.org/10.1073/pnas.0800121105	journal	March 2008
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Shoemaker, A. R.; Mitten, M. J.; Adickes, J. Clinical Cancer Research, Vol. 14, Issue 11 https://doi.org/10.1158/1078-0432.CCR-07-4622	journal	June 2008
Bax and the mitochondrial permeability transition cooperate in the release of cytochrome c during endoplasmic reticulum-stress-induced apoptosis Zhang, D.; Armstrong, J. S. Cell Death & Differentiation, Vol. 14, Issue 4 https://doi.org/10.1038/sj.cdd.4402072	journal	December 2006
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death Boise, Lawrence H.; González-García, Maribel; Postema, Christina E. Cell, Vol. 74, Issue 4 https://doi.org/10.1016/0092-8674(93)90508-N	journal	August 1993
Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation Singh, R. R.; Kim, J. E.; Davuluri, Y. Leukemia, Vol. 24, Issue 5 https://doi.org/10.1038/leu.2010.35	journal	March 2010
Structural Plasticity in a Remodeled Protein-Protein Interface Atwell, S. Science, Vol. 278, Issue 5340 https://doi.org/10.1126/science.278.5340.1125	journal	November 1997
Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family Lee, E. F.; Czabotar, P. E.; Smith, B. J. Cell Death & Differentiation, Vol. 14, Issue 9 https://doi.org/10.1038/sj.cdd.4402178	journal	June 2007
Development of a high-throughput fluorescence polarization assay for Bcl-xL Zhang, Haichao; Nimmer, Paul; Rosenberg, Saul H. Analytical Biochemistry, Vol. 307, Issue 1 https://doi.org/10.1016/S0003-2697(02)00028-3	journal	August 2002
Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction Wendt, Michael D. Expert Opinion on Drug Discovery, Vol. 3, Issue 9 https://doi.org/10.1517/17460441.3.9.1123	journal	August 2008
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53 Irish, Jonathan M.; Ånensen, Nina; Hovland, Randi Blood, Vol. 109, Issue 6 https://doi.org/10.1182/blood-2006-02-004234	journal	November 2006
Predictive biomarkers: a paradigm shift towards personalized cancer medicine La Thangue, Nicholas B.; Kerr, David J. Nature Reviews Clinical Oncology, Vol. 8, Issue 10 https://doi.org/10.1038/nrclinonc.2011.121	journal	August 2011
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL Bruncko, Milan; Oost, Thorsten K.; Belli, Barbara A. Journal of Medicinal Chemistry, Vol. 50, Issue 4 https://doi.org/10.1021/jm061152t	journal	February 2007
Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation Cleary, Michael L.; Smith, Stephen D.; Sklar, Jeffrey Cell, Vol. 47, Issue 1 https://doi.org/10.1016/0092-8674(86)90362-4	journal	October 1986
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia Mason, K. D.; Khaw, S. L.; Rayeroux, K. C. Leukemia, Vol. 23, Issue 11 https://doi.org/10.1038/leu.2009.151	journal	July 2009
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Wilson, Wyndham H.; O'Connor, Owen A.; Czuczman, Myron S. The Lancet Oncology, Vol. 11, Issue 12 https://doi.org/10.1016/S1470-2045(10)70261-8	journal	December 2010
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Gandhi, Leena; Camidge, D. Ross; Ribeiro de Oliveira, Moacyr Journal of Clinical Oncology, Vol. 29, Issue 7 https://doi.org/10.1200/JCO.2010.31.6208	journal	March 2011
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Roberts, Andrew W.; Seymour, John F.; Brown, Jennifer R. Journal of Clinical Oncology, Vol. 30, Issue 5 https://doi.org/10.1200/JCO.2011.34.7898	journal	February 2012
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo Chen, J.; Jin, S.; Abraham, V. Molecular Cancer Therapeutics, Vol. 10, Issue 12 https://doi.org/10.1158/1535-7163.MCT-11-0415	journal	September 2011
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins Park, Cheol-Min; Bruncko, Milan; Adickes, Jessica Journal of Medicinal Chemistry, Vol. 51, Issue 21 https://doi.org/10.1021/jm800669s	journal	November 2008
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo : Navitoclax and bendamustine in lymphoma Ackler, S.; Mitten, Mj; Chen, J. British Journal of Pharmacology, Vol. 167, Issue 4 https://doi.org/10.1111/j.1476-5381.2012.02048.x	journal	September 2012
Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity Harada, H.; Quearry, B.; Ruiz-Vela, A. Proceedings of the National Academy of Sciences, Vol. 101, Issue 43 https://doi.org/10.1073/pnas.0406837101	journal	October 2004
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death Muchmore, Steven W.; Sattler, Michael; Liang, Heng Nature, Vol. 381, Issue 6580 https://doi.org/10.1038/381335a0	journal	May 1996
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells Vaux, David L.; Cory, Suzanne; Adams, Jerry M. Nature, Vol. 335, Issue 6189 https://doi.org/10.1038/335440a0	journal	September 1988
An inhibitor of Bcl-2 family proteins induces regression of solid tumours Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R. Nature, Vol. 435, Issue 7042 https://doi.org/10.1038/nature03579	journal	May 2005
mRNA display selection of a high-affinity, Bcl-X _L -specific binding peptide Matsumura, Nobutaka; Tsuji, Toru; Sumida, Takeshi The FASEB Journal, Vol. 24, Issue 7 https://doi.org/10.1096/fj.09-143008	journal	July 2010
The Bcl-2 apoptotic switch in cancer development and therapy Adams, J. M.; Cory, S. Oncogene, Vol. 26, Issue 9 https://doi.org/10.1038/sj.onc.1210220	journal	February 2007
Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis Sattler, Michael; Liang, Heng; Nettesheim, David Science, Vol. 275, Issue 5302 https://doi.org/10.1126/science.275.5302.983	journal	February 1997
Involvement of the bcl-2 gene in human follicular lymphoma Tsujimoto, Y.; Cossman, J.; Jaffe, E. Science, Vol. 228, Issue 4706 https://doi.org/10.1126/science.3874430	journal	June 1985
Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo Wendt, Michael D.; Shen, Wang; Kunzer, Aaron Journal of Medicinal Chemistry, Vol. 49, Issue 3 https://doi.org/10.1021/jm050754u	journal	February 2006
Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia Marschitz, Ingrid; Tinhofer, Inge; Hittmair, Anton American Journal of Clinical Pathology, Vol. 113, Issue 2 https://doi.org/10.1309/491W-L1TN-UFQX-T61B	journal	February 2000
The management of tumor lysis syndrome Rampello, Elvira; Fricia, Tiziana; Malaguarnera, Mariano Nature Clinical Practice Oncology, Vol. 3, Issue 8 https://doi.org/10.1038/ncponc0581	journal	August 2006
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile Huang, James Z.; Sanger, Warren G.; Greiner, Timothy C. Blood, Vol. 99, Issue 7 https://doi.org/10.1182/blood.V99.7.2285	journal	April 2002
VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia Samuel, Sara; Tumilasci, Vanessa F.; Oliere, Stephanie Molecular Therapy, Vol. 18, Issue 12 https://doi.org/10.1038/mt.2010.188	journal	December 2010
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction Bea, S. Blood, Vol. 106, Issue 9 https://doi.org/10.1182/blood-2005-04-1399	journal	November 2005
miR-15 and miR-16 induce apoptosis by targeting BCL2 Cimmino, A.; Calin, G. A.; Fabbri, M. Proceedings of the National Academy of Sciences, Vol. 102, Issue 39 https://doi.org/10.1073/pnas.0506654102	journal	September 2005
Solution structure of the antiapoptotic protein bcl-2 Petros, A. M.; Medek, A.; Nettesheim, D. G. Proceedings of the National Academy of Sciences, Vol. 98, Issue 6 https://doi.org/10.1073/PNAS.041619798	journal	February 2001
The Hallmarks of Cancer Hanahan, Douglas; Weinberg, Robert A. Cell, Vol. 100, Issue 1 https://doi.org/10.1016/S0092-8674(00)81683-9	journal	January 2000
The BCL-2 protein family: opposing activities that mediate cell death Youle, Richard J.; Strasser, Andreas Nature Reviews Molecular Cell Biology, Vol. 9, Issue 1 https://doi.org/10.1038/nrm2308	journal	January 2008
Programmed Anuclear Cell Death Delimits Platelet Life Span Mason, Kylie D.; Carpinelli, Marina R.; Fletcher, Jamie I. Cell, Vol. 128, Issue 6 https://doi.org/10.1016/j.cell.2007.01.037	journal	March 2007
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Tse, C.; Shoemaker, A. R.; Adickes, J. Cancer Research, Vol. 68, Issue 9 https://doi.org/10.1158/0008-5472.CAN-07-5836	journal	May 2008
BCL2 Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma Iqbal, Javeed; Neppalli, Vishala T.; Wright, George Journal of Clinical Oncology, Vol. 24, Issue 6 https://doi.org/10.1200/JCO.2005.03.4264	journal	February 2006
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Del Gaizo Moore, Victoria; Schlis, Krysta D.; Sallan, Stephen E. Blood, Vol. 111, Issue 4 https://doi.org/10.1182/blood-2007-06-098012	journal	February 2008

Similar Records

Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

Journal Article · Tue Aug 21 00:00:00 EDT 2012 · Journal of Medicinal Chemistry · OSTI ID:1247361

Zhou, Haibin; Aguilar, Angelo; Chen, Jianfang; +8 more

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), A Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significiant in Vivo Antitumor Activity

Journal Article · Sun Jan 01 00:00:00 EST 2006 · Journal of Medicinal Chemistry · OSTI ID:1247361

Chu, X; DePinto, W; Bartkovitz, D; +6 more

Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression

Journal Article · Thu Mar 07 00:00:00 EST 2013 · J. Med. Chem. · OSTI ID:1247361

Chen, Jianfang; Zhou, Haibin; Aguilar, Angelo; +7 more

Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Citation Formats

References (43)

Similar Records

Related Subjects